Glyburide, a sulfonylurea agent for use in Type 2 diabetes, a weak NLRP3 active insulin secretagogue, and its forerunner sulfonamide, 16673-34-0, were added to the INF39 acrylate warhead. Here, NLRP3 is linked to type 2 diabetes mellitus.